Characteristics and prognosis of patients with cryptogenic stroke and suggestive of patent foramen ovale

Jaehuk Choi, Min-Kyung Kang, Jin-Sun Jun, Dong Geum Shin, Donghoon Han, Seonghoon Choi, Jung Rae Cho and Namho Lee

Abstract

Aims: The purpose of this study were to identify the usefulness of screening for PFO using agitated saline echocardiography (ASE) and characteristics and prognosis of patients with suggestive of patent foramen ovale (PFO).

Methods: Three hundred three patients (mean age, 53 ± 9 years; 199 [66%] men) admitted with acute stroke or suspicion of stroke were included. Patients were classified into those with and without right-to-left shunt (RLS) according to the ASE results (positive ASE [n = 92] vs. negative ASE [n = 211]). Fifty-one out of ninety-two patients with positive ASE and twenty-one out of two hundred eleven patients with negative ASE underwent TEE with ASE to confirm PFO.

Results: Ninety-two were positive for ASE and thirty-six of the fifty-one patients who underwent TEE were confirmed as having PFO. Of the patients with RLS grade 1, 50% were diagnosed with PFO and all patients with RLS grade ≥ 2 were diagnosed with PFO. All patients with negative ASE had no PFO (sensitivity of 100% and specificity of 58%). Patients with positive ASE were younger, had a lower body mass, and a lower prevalence of hypertension. The positive ASE patients had a higher mean S’ velocity and better diastolic function. Four of ninety-one patients with positive ASE and thirteen of one hundred seventy-seven showed recurrence of stroke and suspicion of stroke.

Conclusion: Transthoracic ASE is a good method to screen for PFO. Patients with suggestive of PFO had lower risk factors, less atherosclerosis, and better cardiac performance.

Keywords: Cryptogenic stroke, Patent foramen ovale, Agitated saline echocardiography

Introduction

Patent foramen ovale (PFO) has been known to have significant association with cryptogenic ischemic stroke [1]. Despite optimal medical therapy, the rate of stroke recurrence in PFO is estimated to be 25% within a 4-year period [2]. Since the development of percutaneous device closure of PFO as a potential therapeutic option in this group of patients, PFO closure is known to be beneficial as compared to medical therapy in the prevention of recurrent neurological events [3]. The role of echocardiography is very important both in the diagnosis of PFO and in the evaluation of PFO for transcatheter closure [4, 5]. Transesophageal echocardiography (TEE) is considered the gold standard for the diagnosis of PFO because it provides anatomical details [6]. However, TEE requires an expert echocardiographer and is poorly tolerated by patients (more than 40% patients refused TEE in our hospital). In addition, Maggiore, P et al. published an article concerns about TEE with bubble study and the need to diagnose PFO in patients with ischemic stroke [7]. Transcranial Doppler (TCD) might be an alternative method to overcome these limitations of TEE [8]. However, TCD
also is an examiner-dependent method, and cannot be applied in all patients due to difficulties with ultrasound penetration through the skull [9]. Contrast echocardiography using agitated saline contrast is good for detection of right-to-left shunts (RLS) [10]. TEE with agitated saline contrast is a gold standard for diagnosis of PFO for its direct visualization of PFO slit and confirmation of paradoxical RLS. However, sometime it is impossible for TEE to be performed in all patients whom PFO should be screened due to abovementioned pitfalls of TEE. However, transthoracic echocardiography (TTE) with agitated saline contrast (agitated saline echocardiography; ASE) can be used to detect RLS in patients with suspected cryptogenic stroke without any need for expert sonographer or patient’s sedation. Therefore, this study aimed to evaluate the usefulness of transthoracic ASE for screening of PFO and clinical characteristics of suggestive PFO in patients with cryptogenic stroke in South Korea.

**Methods**

This study was a cross-sectional, observational study. In this study, three hundred-three patients (mean age: 53 ± 9, 199 (66%) men) who attended the Kangnam Sacred heart Hospital, Hallym University from the April, 2016 to May, 2018. All patients were referred to division of cardiology for evaluation of cardiac embolic source. Patients with age < 65 and with acute stroke, transient ischemic attack (TIA), or retinal vessel occlusion were included. All patients had undergone TTE, carotid ultrasound, ankle-brachial index (ABI), pulse wave velocity (PWV), 24-h-Holter monitoring, and ASE. We also collected participant data on demographic, anthropometric, and laboratory parameters including cardiac biomarkers. Patients with significant valvular diseases, myocardial infarction, atrial fibrillation (AF), intra-cardiac mass (such as thrombi, myxoma, papillary fibroelastoma, vegetation, et al.), presence of intra-cardiac shunt except PFO, peripheral arterial disease (PAD), significant obstruction (diameter stenosis ≥ 75%) of carotid arteries, or brain hemorrhage were excluded from this study. Study population were divided into two groups – positive ASE (n = 92) vs. negative ASE (n = 211). In addition, TEE was performed to 72 consenting patients to confirm PFO (51 patients with positive ASE and 21 patients with negative ASE agreed to be performed TEE). We observed whether there was a recurrence of stroke or suspicion of stroke in both groups for up to 2 years.

**Echocardiography**

TTE was performed using standard techniques with a 2.5-MHz transducer. The standard 2-D and Doppler echocardiography was performed using a commercially available echocardiographic machine (Vivid 7R GE Medical System, Horten, Norway) with the same setup interfaced with a 2.5-MHz phased-array probe. All measurements were performed according to the guideline [11]. With the study participant in the partial left decubitus position and breathing normally, the observer obtained images from the parasternal long and short axes and from the apical four chamber and two-chamber and long-axis views. Depth setting was optimized to display the LV on the screen as large as possible and the same field depth was kept for both four and two-chamber apical views. Sector width was reduced to increase spatial and temporal resolution. Left ventricular end-diastolic dimensions (LV EDD), end-diastolic interventricular septal thickness (IVSTd), and end-diastolic LV posterior wall thickness (PWTd) were measured at end-diastole according to the standards established by the American Society of Echocardiography. LV ejection fraction (EF) was determined by the biplane Simpson’s method. Maximal left atrial (LA) volume was calculated using the Simpson method and indexed to the body surface area. LV mass was calculated using the Devereux formula = 1.04[(LVEDD + IVSTd + PWTd)3 − (LVEDD)3] − 13.6. Thereafter, the LV mass index (LVMI) was calculated and indexed to body surface area.

Mitral flow velocities were recorded in the apical four-chamber view. Mitral inflow measurements included the peak early (E) and peak late (A) flow velocities and the E/A ratio. The tissue Doppler of the mitral anulus movement was also obtained from the apical four-chamber view. A 1.5-mm sample volume was placed sequentially at the septal annular sites. The analysis was performed for early diastolic (‘E’), late diastolic (‘A’), and systolic (‘S’) peak tissue velocities. As a noninvasive parameter for LV stiffness, the LV filling index (E/E’) was calculated by the ratio of transmitral flow velocity to annular velocity. Adequate mitral and tissue Doppler image (TDI) signals were recorded in all patients.

The mean longitudinal global strain (GS) of LV was calculated from the apical 4,3,2-chamber views by speckle-tracking 2D-strain imaging [12].

**Agitated Saline Echo (ASE)**

Nine millilitre of normal saline agitated with one millilitre of room air, agitated back and forth between two sterile syringes just before intra-venous bolus injection through a forearm vein to detect right to left shunt (RLS) [13]. The injections performed at rest and provocative maneuver (Valsalva maneuver in this study) to increase the right atrial (RA) pressure. The presence of PFO is presumed 3 to 5 cardiac cycles after complete opacification of the RA. We modified the protocol used for shunt grading incorporated 4 grades [8]: grade 1: < 5 bubbles;
grade 2: 5 to 25 bubbles; grade 3: > 25 bubbles; grade 4: opacification of chamber to 3 grades: grade 1: < 5 bubbles only after Valsalva maneuver; grade 2: 5 to 25 bubbles both resting and after Valsalva maneuver; grade 3: > 25 bubbles or opacification (Fig. 1).

Carotid ultrasound

A high-resolution B-mode ultrasound (Vivid 7R GE Medical Systems, Horten, Norway) equipped with a 7.5-MHz linear array transducer was used for carotid ultrasonography. In the longitudinal view, carotid intima-media thickness (IMT) was determined as the distance from the media adventitia interface to the intima lumen interface on the far wall in a region free of plaque [14]. The examiner assessed the presence of carotid plaques, which were defined as focal structures that encroached into the lumen by at least 100% of the surrounding IMT value. Common carotid artery IMT (CCA-IMT) was measured between the origin of the carotid bulb and a point 10 mm proximal to the CCA, and the carotid bulb IMT (CB-IMT) was measured in the carotid bulb region. CCA-IMT and CB-IMT values were determined as the average of the maximum IMT of the left and right CCA and CB.

Pulse Wave Velocity (PWV)

We measured PWV to estimate arterial stiffness, which is generally accepted as the most simple, non-invasive, and validated indicator of arterial stiffness [15]. PWV was measured using a VP-2000 automated device (Colin Co., Komaki, Japan). The right and left brachial-ankle PWV (baPWV) were simultaneously measured. The patients were placed in a supine position about 15 min prior to the test. The pressure waveforms of

Fig. 1 A-1,2: Grade 1—< 5 bubbles within LV only after Valsalva maneuver (yellow arrows: bubbles within LA and LV) LA: left atrium, LV: left ventricle. B-1,2: Grade 2—5 to 25 bubbles within LV both resting and after Valsalva maneuver. C-1,2: Grade 3—> 25 bubbles or opacification within LV
the brachial and tibial arteries were obtained from the occlusion and monitoring cuffs wrapped around the upper arm and lower leg. All measurements were performed in a quiet, temperature-controlled room (22 ± 1 °C), with the patients having fasted overnight. The baseline brachial systolic and diastolic blood pressure (BP), heart rate (HR), and PWV were simultaneously measured.

Statistical analysis
All continuous data are expressed as mean ± SD, and all categorical data are presented as percentage or absolute numbers. Continuous variables were analyzed using Student’s t-test and dichotomous variables were analyzed using the chi square test. Data was statistically analyzed.

| Table 1 | The results of transesophageal echocardiography |
|---------|-----------------------------------------------|
| PFO     | ASE (+), 51                                    |
| Yes     | 36 (71%)                                       |
| no      | 15 (29%)                                       |
| Shunt grade | Gr 0 (21) Gr 1 (30) Gr 2 (7) Gr 3 (14) p       |
| Yes     | 0 (0%)                                         |
| no      | 15 (50%)                                       |
| p       | < 0.001                                        |

PFO patent foramen ovale, ASE agitated saline echo (transthoracic)

| Table 2 | Clinical parameters of the study population |
|---------|---------------------------------------------|
|         | Positive ASE (n = 92)                       |
|         | Negative ASE (n = 211)                      |
|         | p                                           |
| Age (years) | 49.5 ± 10.8                                 | 53.8 ± 8.1 | 0.001 |
| Male gender    | 60 (65.0%)                                  | 139 (65.9%) | 1.000 |
| SBP (mmHg)     | 124.9 ± 17.2                                 | 127.3 ± 16.2 | 0.257 |
| DBP           | 76.8 ± 12.5                                  | 76.9 ± 10.4 | 0.971 |
| Heart rate (bpm) | 69.3 ± 11.2                                 | 67.2 ± 10.4 | 0.108 |
| Body mass index (kg/m²) | 24.1 ± 3.3                                 | 25.0 ± 3.9 | 0.046 |
| Brain MRI     |                                             |             | 0.331 |
| TIA           | 18 (19.6%)                                   | 25 (11.8%) |         |
| Acute stroke  | 53 (57.6%)                                   | 146 (69.2%) |         |
| Small vessel disease | 8 (8.7%)                                   | 17 (8.1%) |         |
| Undetermined  | 13 (14.1%)                                   | 20 (10.9%) |         |
| Any abnormality | 61 (66.3%)                                 | 163 (77.3%) | 0.046 |
| Brain MRA     |                                             |             | 0.282 |
| Normal        | 41 (48.8%)                                   | 85 (40.5%) |         |
| Aneurysm      | 14 (16.1%)                                   | 363 (17.1%) |         |
| Stenosis      | 31 (36.9%)                                   | 101 (48.1%) | 0.092 |
| Vasculitis et al | 5 (6.0%)                                   | 7 (3.3%) |         |
| Thrombolysis  | 2 (1.7%)                                     | 10 (5.6%) | 0.133 |
| Hypertension  | 28 (30.4%)                                   | 92 (43.6%) | 0.041 |
| Diabetes      | 15 (16.3%)                                   | 46 (21.8%) | 0.350 |
| Prior events  | 8 (8.7%)                                     | 26 (12.3%) | 0.432 |
| RoPE score    | 5.73 ± 1.51                                  | 4.99 ± 1.54 | <0.001 |
| Current smoker | 43 (46.7%)                                  | 95 (45.0%) | 0.803 |
| Medications   |                                             |             |        |
| Aspirin       | 1 (1.1%)                                     | 18 (8.6%) | 0.010 |
| RASB          | 15 (16.3%)                                   | 40 (19.0%) | 0.629 |
| Statin        | 8 (8.7%)                                     | 28 (13.3%) | 0.335 |
| aPFO device therapy  | 6 (6.6%)                                    | 0 | 0.001 |
| Recurrence    | 4 (4.7%)                                     | 13 (6.2%) | 0.407 |
| Loss of follow up | 11 (1.1%)                                  | 34 (16.1%) | 0.001 |

Data are mean ± standard deviation (SD) or n (%)
ASE agitated saline echo, SBP systolic blood pressure, DBP diastolic BP, MRI magnetic resonance image, TIA transient ischemic attack, MRA magnetic resonance angiography, RASB Renin-Angiotensin system blocker, CCB calcium-channel blocker, OHA oral hypoglycemic agents, PFO patent foramen ovale

a Device therapy was performed in 6 patients with PFO confirmed by transesophageal echocardiography, and all were ASE grade 3
using SPSS version 20, and \( p \)-value < 0.05 was considered statistically significant for all the analyses. Significant factors were tested in a univariate binary logistic regression analysis, and then only significant variables were entered in a stepwise multivariate logistic regression analysis to identify the independent predictors for the positive ASE. In addition, multivariate analysis (logistic regression) was performed.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The local institutional review board approved this study (IRB file No.: HKS 2018–01–014). Informed consent was not obtained from all individual participants included in the study, because this study was a cross-sectional, observational study.

Results
Clinical parameters of the study population
Of the 303 patients, 92 were positive ASE, while 36 of 51 (71%) patients who underwent TEE were confirmed as having PFO. Among the patients with grade 1 RLS, 50% were diagnosed with PFO; in contrast, all patients with RLS grade ≥ 2 RLS were diagnosed with PFO (Table 1). On the other hand, no patients with negative ASE were diagnosed with PFO on TEE (sensitivity of 100% and specificity of 58%). The patients’ clinical characteristics are shown in Table 2. The study population included 303 patients (mean age, 53 ± 9 years; 199 [66%] men) who were admitted for acute stroke or suspicion. Patients with positive ASE were significantly younger and had lower body mass index (BMI). The prevalence of hypertension was also lower in significantly younger and had lower body mass index (BMI). The prevalence of hypertension was also lower in patients with positive ASE group. Brain magnetic resonance imaging (MRI) showed a similar frequency of acute stroke or TIA. However, the incidence of any abnormality on brain MRI including undetermined lesions was lower in patients with positive ASE; also, patients with positive ASE had higher S’ velocity and better diastolic function (higher E’ and A’ velocities and more favorable LV filling pattern). In addition, LV dimension and LVMI were slightly smaller and LV EF was slightly higher in patients with positive ASE with marginal statistical significance.

Echocardiographic parameters of the study population
Table 3 shows the patients’ echocardiographic parameters; no significant intergroup differences were seen in cardiac size or LV systolic function. However, patients with positive ASE had higher S’ velocity and better diastolic function (higher E’ and A’ velocities and more favorable LV filling pattern). In addition, LV dimension and LVMI were slightly smaller and LV EF was slightly higher in patients with positive ASE with marginal statistical significance.

Laboratory findings and other parameters
Table 4 shows laboratory parameters and carotid ultrasound results. There were no significant intergroup differences in blood test results. The values of PWV, an indicator of arterial stiffness, were lower in patients with positive ASE. In addition, IMT was lower and the presence of carotid plaque was significantly lower in patients with positive ASE. However, there was no significant intergroup difference in maximal thickness of the carotid plaques.

Table 3  Echocardiographic parameters of the study population

|                      | Positive ASE (n = 92) | Negative ASE (n = 211) | \( p \) |
|----------------------|----------------------|------------------------|--------|
| LAVI (ml/m²)         | 23.5 ± 7.0           | 23.9 ± 7.3             | 0.695  |
| LV SWT'd (mm)        | 9.6 ± 1.8            | 9.9 ± 1.7              | 0.199  |
| LV PW'Td             | 9.4 ± 1.7            | 9.7 ± 1.6              | 0.177  |
| LV EDD (mm)          | 48.5 ± 4.2           | 49.4 ± 4.0             | 0.071  |
| LV ESD               | 30.9 ± 3.4           | 31.7 ± 4.0             | 0.069  |
| LVMI (g/m²)          | 96.1 ± 26.5          | 101.5 ± 23.8           | 0.078  |
| LV EF (%)            | 65.5 ± 4.9           | 64.5 ± 4.9             | 0.108  |
| GS (%)               | -17.8 ± 3.2          | -18.0 ± 3.0            | 0.636  |
| E (cm/s)             | 68.3 ± 18.3          | 68.4 ± 16.7            | 0.945  |
| A (cm/s)             | 67.9 ± 18.9          | 71.2 ± 17.1            | 0.134  |
| E/A ratio            | 1.10 ± 0.41          | 1.02 ± 0.39            | 0.105  |
| DT (ms)              | 199.6 ± 39.2         | 208.0 ± 43.5           | 0.116  |
| E’ (cm/s)            | 8.2 ± 3.0            | 7.5 ± 2.8              | 0.031  |
| A’ (cm/s)            | 9.6 ± 2.1            | 9.1 ± 1.7              | 0.020  |
| E/A’                 | 0.9 ± 0.4            | 0.9 ± 0.4              | 0.607  |
| E/E’                 | 9.3 ± 4.3            | 10.0 ± 3.3             | 0.123  |
| S’ (cm/s)            | 8.0 ± 1.7            | 7.3 ± 1.4              | <0.001 |
| RVSP                 | 27.4 ± 6.1           | 27.4 ± 5.4             | 0.378  |

Diastolic grade

|                      | normal   | Grade 1 | Grade 2 |
|----------------------|----------|---------|---------|
|                       | 40 (43.5%) | 47 (51.1%) | 5 (5.6%) |
|                       | 71 (34.3%) | 134 (64.7%) | 2 (1.0%) |

Data are represented as mean ± SD or n (%)

LAVI left atrial volume index, LVMI left ventricular mass index, SWT’d diastolic septal wall thickness, SWT’d systolic SWT, PW’T’d diastolic posterior wall thickness, sPW’T’d systolic PWT, OWS diastolic wall strain, LV EDD and ESD LV end-diastolic and systolic dimension, EF ejection fraction, GS global strain, DT deceleration time, RVSP right ventricular systolic pressure
Univariate and multivariate analyses (Table 5)
Among the various parameters, univariate analysis was performed with parameters with a \( p \) value of less than 0.5. Univariate analysis showed that several clinical, echocardiographic, and other factors had predictive value for positive ASE. Younger age, lower BMI, lower prevalence of hypertension, less aspirin use, more favorable diastolic function, elevated E’ and A’ velocities, lower PWV, lower IMT, and lower presence of carotid plaque were associated with positive ASE. Multivariate analysis was performed with a parameter with a \( p \) value of less than 0.5 in univariate analysis.

Among variables found to be correlated with positive ASE, lower BMI (odds ratio [OR], 0.903; 95% confidence interval [CI], 0.821–0.994; \( p = 0.036 \)) and higher A’ velocity (OR, 1.280; 95% CI, 1.048–1.563; \( p = 0.015 \)) were independently correlated with positive ASE in patients with acute stroke or suspected stroke.

Discussion
The novel findings of this study are that transthoracic ASE is an easy and convenient screening tool for PFO and that the greater the RSL degree, the higher the likelihood of PFO. Patients with positive ASE showed similar stroke severity and recurrence rate to those with negative ASE, but they were relatively younger, had a lower mean BMI, had a lower prevalence of hypertension, had less atherosclerosis, and had better cardiac performance. In addition, patients with positive ASE showed used much less aspirin.

Characteristics of cryptogenic stroke and suggestive of PFO
Embolic stroke of undetermined source (ESUS) was introduced to identify patients with nonlacunar cryptogenic ischemic strokes in whom embolism was the likely stroke mechanism [17]. The characteristics of ESUS patients according to the review that emerged are of relatively young (compared with AF-associated stroke) patients with mild strokes and lower frequencies of conventional vascular risk factors than non-ESUS patients with ischemic stroke [18]. We also evaluated the clinical impact of PFO in patients <65 years with cryptogenic stroke. The results were similar, suggesting that fewer conventional risk factors are found in patients with suspected PFO (as positive ASE), although the degree of severity was similar on brain MRI. TEE was performed in 21 consenting patients with negative ASE, all without PFO. On the other hand, PFO was confirmed in 36 of 51 (71%) positive ASE patients who underwent TEE (sensitivity of 100% and specificity of 58%). According to shunt grade, PFO was confirmed in all patients with RLS grade \( \geq 2 \), but 15 (50%) of 30 patients with a grade 1 shunt demonstrated no PFO on TEE with ASE, which showed that the greater the RSL degree, the higher the likelihood of

Table 4  Laboratory and other parameters

| Parameter                  | Positive ASE (n = 92) | Negative ASE (n = 211) | \( p \)  |
|----------------------------|----------------------|------------------------|--------|
| D-dimer (μg/dL)            | 0.18 ± 0.05          | 0.28 ± 0.28            | 0.487  |
| Serum creatinine (mg/dL)   | 0.90 ± 0.82          | 0.86 ± 0.67            | 0.695  |
| GFR (mL/min/1.73m²)        | 84.1 ± 14.1          | 83.8 ± 12.8            | 0.869  |
| Total cholesterol (mg/dL)  | 185.4 ± 38.2         | 193.2 ± 40.0           | 0.119  |
| LDL (mg/dL)                | 112.8 ± 37.6         | 117.4 ± 33.1           | 0.314  |
| HDL                        | 46.7 ± 14.2          | 45.8 ± 13.5            | 0.607  |
| BNP (pg/mL)                | 51.9 ± 86.9          | 37.6 ± 45.8            | 0.191  |
| Troponin I (ng/mL)         | 0.011 ± 0.026        | 0.007 ± 0.09           | 0.359  |
| aTG (mg/dL)                | 115 (30–458)         | 135 (24–1575)          | 0.401  |
| aCK-MB (ng/mL)             | 1.05 (0.18–20.39)    | 1.15 (0.02–34.19)      | 0.782  |
| PWV (m/s)                  | 1.62 ± 0.51          | 1.72 ± 0.37            | 0.034  |
| IMT (mm)                   | 0.66 ± 0.19          | 0.74 ± 0.23            | 0.007  |
| Carotid plaque             | 51 (61%)             | 160 (76%)              | 0.010  |
| Maximal plaque (mm)        | 2.10 ± 0.79          | 2.22 ± 0.79            | 0.336  |
| ABI,rt                     | 1.19 ± 0.07          | 1.17 ± 0.08            | 0.688  |
| ABI,lt                     | 1.19 ± 0.08          | 1.16 ± 0.09            | 0.108  |

Data are expressed as mean ± SD
GFR glomerular filtration ratio, LDL low density lipoprotein, HDL high density lipoprotein, BNP Brain natriuretic peptide, TG triglyceride, CK-MB Creatine kinase-MB, PWV pulse wave velocity, IMT intima-medial thickness, ABI ankle-brachial index

a Analyzed by Mann–Whitney U test and data are expressed as median (IQR)
PFO. As suggested in previous study [16], the higher the RoPE score, the more likely the association between cryptogenic stroke and PFO. Although this study did not confirm PFO in all patients with positive ASE, the RoPE score was significantly higher in patients with positive ASE. The biggest drawback of this study is that the diagnosis rate of PFO according to the results of ASE was not compared head to head by performing TEE in all patients.

**Clinical obstacles in implementing TEE**
Since many patients in real clinical setting do not want to perform TEE, and TEE may not be needed in all patients in various economic and medical aspects, the results of ASE may be helpful in selectively implementing TEE in patients in need. Therefore, inferring the results of this study suggests that the higher the shunt grade of the transthoracic ASE, the higher the probability of stroke due to PFO, which may be considered for treatment. Reinthaler M. et al. recently published that PFO closure plus antiplatelets was superior in terms of stroke prevention compared to medical treatment alone, especially in patients with moderate to severe shunt and those younger than 45 years of age [18]. We then examined the cause of grade I shunt in transthoracic ASE without PFO on TEE with ASE. First, it is possible that the Valsalva maneuver was not exactly accurate at the time of TEE. It is extremely important to continue echocardiographic imaging during the strain and release phases of the Valsalva maneuver to prevent missing the diagnosis of a paradoxical shunt [19]. Second, the imaging resolution of TTE was insufficient; therefore, it is possible that an artifact in the LA was misunderstood as a few bubbles. Finally, a physiologic shunt (venous admixture) may have occurred in which a fraction of mixed venous blood does not become oxygenated as it moves from the RA to the LA and LV [20]. There were no significant differences in age, sex, or other risk factors between the patients with a grade I shunt with versus without PFO. In this study, we checked patients’ follow up to 2 years, and investigated recurrence of stroke in the meantime. Although not statistically significant, the recurrence rate was low in patients with positive ASE. Since the patients enrolled in this study were relatively younger patients with cryptogenic stroke (less than 65 years old), it is thought that the recurrence rate was low and the prognosis was not bad in both groups. And although there is no clear evidence for doing follow up better in patients with positive ASE patients than in patients with negative ASE patients, it might be due to patients’ more concerns about additional heart problem.

**Table 5** Uni- and multivariate analysis of relating factors for positive result of ASE

|                        | Odds ratio | 95% CI       | p       |
|------------------------|------------|--------------|---------|
| **Univariate analysis**|            |              |         |
| Any abnormality on brain MRI | 0.579     | 0.338–0.993  | 0.047   |
| Age                    | 0.952     | 0.927–0.978  | <0.001  |
| BMI                    | 0.924     | 0.855–0.998  | 0.045   |
| Hypertension           | 0.566     | 0.336–0.953  | 0.032   |
| Aspirin                | 0.117     | 0.015–0.892  | 0.038   |
| E’                     | 1.100     | 1.008–1.199  | 0.032   |
| A’                     | 1.170     | 1.023–1.338  | 0.022   |
| S’                     | 1.353     | 1.144–1.600  | <0.001  |
| LV diastolic dysfunction| 0.842     | 0.527–1.346  | 0.473   |
| PWV                    | 0.999     | 0.998–1.000  | 0.036   |
| IMT                    | 0.130     | 0.030–0.564  | 0.006   |
| Carotid plaque         | 0.483     | 0.281–0.829  | 0.008   |
| **Multivariate analysis**|          |              |         |
| Any abnormality on brain MRI | 0.878     | 0.451–1.709  | 0.701   |
| age                    | 0.975     | 0.936–1.017  | 0.241   |
| BMI                    | 0.903     | 0.821–0.994  | 0.036   |
| Hypertension           | 0.817     | 0.428–1.557  | 0.539   |
| Aspirin                | 0.179     | 0.022–1.470  | 0.109   |
| E’                     | 0.923     | 0.804–1.058  | 0.250   |
| A’                     | 1.280     | 1.048–1.563  | 0.015   |
| S’                     | 1.180     | 0.920–1.513  | 0.193   |
| PWV                    | 1.000     | 0.999–1.001  | 0.504   |
| IMT                    | 0.216     | 0.039–1.190  | 0.078   |
| Carotid plaque         | 0.634     | 0.327–1.231  | 0.634   |

BMI: body mass index, LV: left ventricular, PWV: pulse wave velocity, IMT: intima-medial thickness

**Role of echocardiography in patients with stroke**
The role of echocardiography in patients with stroke is not only to find structural heart disease or intracardiac mass but also to screen for PFO, especially in young patients who present with cryptogenic stroke and no cardiovascular risk factors [21]. Here we excluded patients with significant structural heart diseases or other abnormalities, so there were no significant intergroup differences in echocardiographic results. Nonetheless, diastolic performance was better in patients with positive ASE. In particular, A’ velocity of the mitral annulus using tissue Doppler imaging was slightly higher with statistical significance. A’ velocity is a good parameter for LA contractile function, and both systolic and diastolic function affect LA contractile function. A higher LV EF is associated with higher
A’ velocity, while restrictive LV diastolic filling is associated with lower A’ velocity [22]. Although there was no significant intergroup difference in EF, this study also suggests that A’ velocity was significantly higher in patients with positive ASE because of higher S’ velocity and better diastolic performance.

Other factors associated with stroke
Carotid atherosclerosis (carotid stiffness, IMT, and early plaque formation) is a marker of systemic atherosclerosis and a predictor of ischemic cerebrovascular disease (CVD) [23]. Increased carotid IMT and the presence of carotid plaques are well established predictors of CVD and ischemic stroke [24]. Likewise patients with a positive ASE had lower carotid IMT and fewer carotid plaques in this study.

It is well known that increased arterial stiffness (IAS) is an early marker of systemic atherosclerosis and has independent predictive value for cardiovascular events [25]. The PWV was also higher in patients with negative ASE.

Role of transthoracic agitated saline echocardiography in treatment
A recent meta-analysis of randomized controlled trials of PFO showed that in selected patients with cryptogenic stroke, PFO closure is superior to medical therapy for preventing further strokes, which was particularly true for patients with moderate to large shunts [26]. The long-term follow-up data clarified that, with good patient selection, transcatheter PFO closure significantly reduces the risk of recurrent stroke compared with medical therapy in patients with cryptogenic stroke with no increased risk of serious adverse events or influence on major bleeding [27]. Therefore, as well as the presence of PFO, shunt grade is also an important consideration in the management of PFO with stroke, so it may be necessary to screen for PFO and confirm shunt grade using transthoracic ASE, which is more comfortable for the patient.

Here, we suggest a diagnostic algorithm for patients with suspected cardiac embolic stroke according to our results (Fig. 2).

Study limitations
TEE was not performed in many patients in this study. This was a major limitation of this study because of high possibility of selection bias; however, it was the main purpose of this study because most patients refuse TEE, transthoracic ASE was performed to screen for PFO and elucidate the clinical significance of the results. In addition, if TEE is impossible to do, we can consider other test, such as transcranial Doppler to confirm PFO in subsequent studies or clinical settings.

---

**Fig. 2** Suggested diagnostic algorithm for patients with suspected cardiac embolic stroke. CES: cardiac embolic stroke, MI: myocardial infarction, ASE: agitated saline echocardiography, PFO: patent foramen ovale, TEE: transesophageal echocardiography.
Conclusions
In summary, transthoracic ASE is an easy and convenient screening tool for PFO, and the greater the degree of RSL, the higher the likelihood of PFO. Patients with positive ASE showed similar stroke severity to those with negative ASE, but they were relatively younger, had a lower mean BMI, had a lower prevalence of hypertension, less commonly had atherosclerosis, and had better cardiac performance. Our findings suggest that transthoracic ASE may be a good screening method for PFO and helpful in the diagnosis and treatment of PFO in patients with relatively low risk factors, good cardiac performance, and confirmed or suspected stroke.

Abbreviations
PFO: Patent foramen ovale; TEE: Transesophageal echocardiography; TCD: Transcranial Doppler; RLS: Right-to-left shunts; TTE: Transthoracic echocardiography; ASE: Agitated saline echocardiography; TIAD: Transient ischemic attack; ABI: Ankle-brachial index; PWV: Pulse wave velocity; LV: Left ventricular; AF: Atrial fibrillation; PAD: Peripheral arterial disease; LV: Left ventricular; EDD: End-diastolic dimensions; IVSTd: End-diastolic interventricular septal thickness; EF: Ejection fraction; LA: Left atrial; LVMi: LV mass index; TDI: Tissue Doppler imaging; GS: Global strain; IMT: Intima-media thickness; CCA: Common carotid artery; CB: Carotid bulb; ESUS: Embolic stroke of undetermined source; CVD: Cerebrovascular disease; IAS: Increased arterial stiffness.

Acknowledgements
There is nothing to declare with this study.

Authors’ contributions
J Choi and MK Kang designed this study as the first author and corresponding author. JS Jun helped in analyzing MRI images. DG shin, DH Han, S Choi, JR Cho, N Lee were involved in data acquisition and analysis in this study. The author(s) read and approved the final manuscript.

Funding
This research received no specific grant from any funding agency.

Availability of data and materials
The whole images or part of it, neither has been published and is not being considered for publication elsewhere in whole or part in any language.

Declarations
Ethics approval and consent to participate
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication
Not Applicable.

Competing interests
There are no conflicts of interest in this study.

Author details
1 Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University Medical Center, Seoul, South Korea. 2 Division of Cardiology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, South Korea. 3 Division of Neurology, Kangnam Sacred Heart Hospital, Hallym University Medical Center, Seoul, South Korea.

References
1. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. PFO in Cryptogenic Stroke Study (PICSS); PFO in Cryptogenic Stroke Study (PICSS) Investigators. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation. 2002;105(22):2625–31.
2. Mas JL, Arquizan C, Lamy C, Miot JL, Arquizan C, Lamy C, et al. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. N Engl J Med. 2001;345(24):1740–6.
3. Khan AR, Bin Abdulhak AA, Sheikh MA, Khan S, Erwin PJ, Tepley J, et al. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis. JACC Cardiovasc Interv. 2013;6(12):1316–23.
4. Rana BS, Thomas MR, Calvert PA, Monaghan MJ, Hildick-Smith D. Echocardiographic evaluation of patent foramen ovale prior to device closure. JACC Cardiovasc Imaging. 2010;3(7):749–60.
5. Abdelghani M, El-Shedouyou S, Nassif M, Bouna BL, de Winter RJ. Management of Patients with Patent Foramen Ovale and Cryptogenic Stroke: An Update. Cardiology. 2019;143(1):63–72.
6. Nakanishi K, Yoshiyama M, Homma S. Patent foramen ovale and cryptogenic stroke. Trends Cardiovasc Med. 2017;27(8):575–81.
7. Maggiore P, Bellingi J, Chien D, White D, Lan NS, Jaltotate B, et al. Ischaemic Stroke and the Echocardiographic “Bubble Study”: Are We Screening the Right Patients? Heart Lung Circ. 2018;28(1):1183–9.
8. Jauss M, Kaps M, Keberle M, Dorndorf W. A comparison of transesophageal echocardiography and transcranial Doppler sonography with contrast medium in the detection of patent foramen ovale. Stroke. 1994;25(6):1265–7.
9. Sorteverg A, Sorteverg W. Transcranial Doppler Ultrasonography. Part III: Pitfalls in Methodology and Evaluation of the Cerebral Collateral Capacity. Contemp Neurol. 2017;29:1–8.
10. Meerbaum S. Introduction and general background. In: Meerbaum S, Meltzer R, editors. Myocardial Contrast Two-Dimensional Echocardiography. Boston: Kluwer Academic Publishers; 1989.
11. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(11):1–39.
12. Dandel M, Lehmkuhl H, Kosalla C, Suramaleshwari N, Hetzer R. Strain and strain rate imaging by echocardiography - basic concepts and clinical applicability. Curr Cardiol Rev. 2009;5(2):133–48.
13. Porter TR, Abdelmonime S, Beleik JT, McCulloch ML, Mulvagh SL, Olson JJ, et al. Guidelines for the cardiac sonographer in the performance of contrast echocardiography: a focused update from the American Society of Echocardiography. J Am Soc Echocardiogr. 2014;27(8):797–810.
14. Touboul PJ, Hennerici MG, Meairs S, Adams H, Amarenco P, Bornstein N, et al. Mannheim carotid intima-media thickness and plaque consensus (2004–2006–2011). An update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290–6.
15. Tomlinson LA. Methods for assessing arterial stiffness: technical consider-ations. Curr Opin Nephrol Hypertens. 2012;21(6):655–60.
16. Thaler DE, Ruthazer R, Weimar C, Mas JL, Serena J, Di Angelantonio E, et al. Recurrent stroke predictors differ in medically treated patients with pathogenic vs. other PTOs. Neurology. 2014;83(12):221–6.
17. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al. Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13(4):3429–38.
18. Reithmayer M, Ozga AK, Sinning D, Cunio J, Al-Hindawi HS, Backemo Johansson J, et al. Revival of transcatheter PFO closure: A meta-analysis of randomized controlled trials - impact of shunt size and age. Am Heart J. 2018;201:95–102.
19. Cheng TO. Paradoxical embolism. A diagnostic challenge and its detection during life. Circulation. 1976;53:565–8.
20. Wagner PD. Ventilation/perfusion relationships. Clin Physiol. 1981;15:437–51.
21. Saric M, Armour AC, Amaout MS, Chaudhry FA, Grimm RA, Kronzon I, et al. Guidelines for the Use of Echocardiography in the Evaluation of a Cardiac Source of Embolism. J Am Soc Echocardiogr. 2016;29(1):1–42.
22. Blume GG, Mcleod CJ, Barnes ME, Seward JB, Pellikka PA, Bastiansen PM, et al. Left atrial function: physiology, assessment, and clinical implications. Eur J Echocardiogr. 2011;12(6):421–30.
23. Rothwell PM. Carotid artery disease and the risk of ischaemic stroke and coronary vascular events. Cerebrovasc Dis. 2000;10(5):21–33.
24. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen TP, et al. PROG-iMT Study Group. Lancet. 2012;379(9831):2053–62.
25. Willum-Hansen T, Staessen JA, Torp-Pedersen C, Thøjs L, Ibsen H, Jøppesén J. Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation. 2006;113(5):664–70.
26. Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, et al. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. Eur Heart J. 2018;39(18):1638–49.
27. Mojadidi MK, Zaman MO, Elgendy IY, Mahmoud AN, Patel NK, Agarwal N, et al. Cryptogenic Stroke and Patent Foramen Ovale. J Am Coll Cardiol. 2018;71(9):1035–43.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.